DRNA Dicerna Pharmaceuticals, Inc. Stock Quote

DRNA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.61	Insider Own	0.10%	Shs Outstand	74.52M	Perf Week	1.20%
Market Cap	1.74B	Forward P/E	-	EPS next Y	-1.03	Insider Trans	-93.69%	Shs Float	68.75M	Perf Month	-0.72%
Income	-115.80M	PEG	-	EPS next Q	-0.05	Inst Own	79.70%	Short Float	8.60%	Perf Quarter	14.03%
Sales	130.40M	P/S	13.37	EPS this Y	-10.20%	Inst Trans	-1.14%	Short Ratio	9.01	Perf Half Y	3.56%
Book/sh	2.06	P/B	11.44	EPS next Y	4.60%	ROA	-16.60%	Target Price	35.00	Perf Year	11.28%
Cash/sh	8.24	P/C	2.86	EPS next 5Y	-	ROE	-71.70%	52W Range	11.75 - 27.10	Perf YTD	6.99%
Dividend	-	P/FCF	8.76	EPS past 5Y	10.10%	ROI	-84.20%	52W High	-13.03%	Beta	1.10
Dividend %	-	Quick Ratio	2.60	Sales past 5Y	-	Gross Margin	-	52W Low	100.60%	ATR	1.22
Employees	187	Current Ratio	2.60	Sales Q/Q	511.30%	Oper. Margin	-94.30%	RSI (14)	53.16	Volatility	5.09% 5.05%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	34.90%	Profit Margin	-88.80%	Rel Volume	1.70	Prev Close	24.35
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 05 AMC	Payout	-	Avg Volume	656.61K	Price	23.57
Recom	1.60	SMA20	3.24%	SMA50	1.50%	SMA200	9.63%	Volume	1,119,332	Change	-3.20%

Aug-07-20

Reiterated

H.C. Wainwright

Buy

$32 → $35

May-13-20

Initiated

RBC Capital Mkts

Outperform

$35

Mar-19-20

Initiated

Berenberg

Buy

$35

Nov-19-19

Reiterated

H.C. Wainwright

Buy

$22 → $30

Oct-29-19

Initiated

Robert W. Baird

Outperform

May-24-19

Resumed

Citigroup

Buy

$30

Jan-22-19

Upgrade

Chardan Capital Markets

Neutral → Buy

$18

Nov-06-18

Upgrade

B. Riley FBR

Neutral → Buy

$13.50 → $21

Sep-13-18

Initiated

Citigroup

Buy

$27

Aug-15-18

Upgrade

H.C. Wainwright

Neutral → Buy

$21

Aug-09-18

Reiterated

Stifel

Buy

$18 → $20

Mar-28-18

Initiated

B. Riley FBR, Inc.

Neutral

$10

Mar-23-18

Downgrade

H.C. Wainwright

Buy → Neutral

$12

Mar-09-18

Initiated

Chardan Capital Markets

Neutral

Feb-05-18

Initiated

SunTrust

Buy

$13

Jan-16-18

Initiated

Evercore ISI

Outperform

$14

Nov-03-17

Reiterated

H.C. Wainwright

Buy

$6 → $10

May-23-17

Resumed

H.C. Wainwright

Buy

Apr-10-17

Reiterated

H.C. Wainwright

Buy

$8 → $5

Jan-31-17

Resumed

Leerink Partners

Mkt Perform

Jan-06-21 02:05AM	Should You Take Comfort From Insider Transactions At Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)? Simply Wall St.
Jan-05-21 04:05PM	Dicerna to Participate in the H.C. Wainwright Virtual BioConnect Conference Business Wire
07:30AM	Dicerna Announces Novo Nordisks Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement Business Wire
Jan-04-21 05:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
07:30AM	Dicerna Announces Enrollment Completion of PHYOX2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria Business Wire
Dec-22-20 09:44AM	Is the Options Market Predicting a Spike in Dicerna (DRNA) Stock? Zacks
Dec-20-20 03:25PM	Is DRNA A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-11-20 09:01AM	Is Dicerna Pharmaceuticals (DRNA) a Smart Long-term Buy? Insider Monkey
Dec-01-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-16-20 07:31AM	Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLDs The Liver Meeting® Digital Experience 2020 Business Wire
07:30AM	Dicerna Announces FDA Acceptance of Lillys Investigational New Drug (IND) Application for First GalXC RNAi Candidate Under Companies Global Research Collaboration and Licensing Agreement Business Wire
Nov-11-20 04:05PM	Dicerna to Participate in Upcoming Investor Conferences Business Wire
Nov-10-20 04:05PM	Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020 Business Wire
Nov-09-20 02:42PM	Was The Smart Money Wrong About Piling Into Dicerna Pharmaceuticals Inc (DRNA)? Insider Monkey
Nov-07-20 08:54AM	Earnings Update: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Just Reported And Analysts Are Boosting Their Estimates Simply Wall St.
Nov-06-20 02:30PM	Dicerna Pharmaceuticals Inc (DRNA) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 04:05PM	Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update Business Wire
02:30PM	Dicerna Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-01-20 12:00PM	Dicerna Announces Updated Phase 1 Data on RG6346 Investigational Treatment for Chronic Hepatitis B Virus to be Presented in Late-Breaking Session at AASLDs The Liver Meeting® Digital Experience 2020 Business Wire
Oct-29-20 04:05PM	Dicerna to Report Third Quarter 2020 Financial Results on November 5, 2020 Business Wire
12:34PM	Will Dicerna Pharmaceuticals (DRNA) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-26-20 11:54PM	5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month) Insider Monkey
Oct-22-20 10:05AM	Dicerna Presents Positive New Interim Data From PHYOX3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH) Business Wire
Oct-15-20 04:12PM	Vertex Tumbles As It Stops Testing On Protein Deficiency Treatment Investor's Business Daily +6.55%
Oct-13-20 04:05PM	Dicerna to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference Business Wire
07:00AM	VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors GlobeNewswire
Oct-09-20 04:05PM	Dicerna to Present Nedosiran Data at American Society of Nephrology (ASN) Kidney Week 2020 Business Wire
Oct-01-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-28-20 04:05PM	Dicerna to Participate in the Chardan 4th Annual Genetic Medicines Conference Business Wire
Sep-16-20 04:24PM	Arrowhead Pharma Reveals Positive Data On Drug To Treat Liver Disease; ARWR Stock Jumps Investor's Business Daily +6.94%
07:30AM	Dicerna Appoints Ling Zeng as Chief Legal Officer and Secretary Business Wire
Sep-10-20 04:17PM	Hedge Funds Have Never Been This Bullish On Dicerna Pharmaceuticals Inc (DRNA) Insider Monkey
Sep-02-20 04:05PM	Dicerna to Participate in Upcoming September Investor Conferences Business Wire +5.38%
Sep-01-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-06-20 08:35AM	Dicerna Pharmaceuticals (DRNA) Reports Q2 Loss, Misses Revenue Estimates Zacks -8.17%
07:01AM	Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Technology in New Tissues Business Wire
07:00AM	Dicerna Announces Second Quarter 2020 Financial Results and Provides a Business Update Business Wire
Aug-05-20 04:05PM	Dicerna Announces Appointment of Shreeram Aradhye, M.D., as Executive Vice President and Chief Medical Officer Business Wire
Aug-03-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +6.51%
Jul-30-20 12:33PM	Dicerna Pharmaceuticals (DRNA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Jul-24-20 07:30AM	Dicerna to Report Second Quarter 2020 Financial Results and Host Virtual Research and Development Event on Aug. 6, 2020 Business Wire
Jul-21-20 08:11AM	2 Stocks to Hold for the Next 20 Years Motley Fool -6.45%
Jul-20-20 11:06AM	Did Hedge Funds Make The Right Call On Dicerna Pharmaceuticals Inc (DRNA) ? Insider Monkey +8.35%
Jul-01-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-18-20 07:30AM	Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria Business Wire +5.45%
Jun-15-20 08:49AM	Hedge Funds Arent Crazy About Dicerna Pharmaceuticals Inc (DRNA) Anymore Insider Monkey +7.78%
Jun-12-20 08:31AM	2 Top Small-Cap Stocks to Buy Right Now Motley Fool
Jun-08-20 03:24AM	Alnylam Reveals Solid Lumasiran Results; Analyst Says Dicerna Better Pick SmarterAnalyst
Jun-05-20 09:40AM	Edited Transcript of DRNA earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-01-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-26-20 04:05PM	Dicerna to Participate in Jefferies Virtual Global Healthcare Conference Business Wire -5.84%
May-18-20 06:29AM	Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Analysts Are Way More Bearish Than They Used To Be Simply Wall St. +8.49%
May-12-20 04:05PM	Dicerna to Present at Upcoming May Investor Conferences Business Wire
May-10-20 10:39PM	Were Hedge Funds Right About Dicerna Pharmaceuticals Inc (DRNA)? Insider Monkey
09:23AM	Dicerna Pharmaceuticals, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next Simply Wall St.
May-09-20 04:31PM	Dicerna Pharmaceuticals Inc (DRNA) Q1 2020 Earnings Call Transcript Motley Fool
May-08-20 07:59AM	The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda Benzinga -8.80%
May-07-20 06:45PM	Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:05PM	Dicerna Announces First Quarter 2020 Financial Results and Provides a Business Update Business Wire
04:01PM	Dicerna Announces Appointment of Douglas Pagán as Chief Financial Officer Business Wire
02:59PM	11 Small-Cap Stocks Analysts Love the Most Kiplinger
May-01-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-30-20 04:05PM	Dicerna to Report First Quarter 2020 Financial Results on May 7, 2020 Business Wire -7.12%
Apr-29-20 07:36AM	We're Not Worried About Dicerna Pharmaceuticals's (NASDAQ:DRNA) Cash Burn Simply Wall St.
Apr-08-20 06:00AM	Biotech vet Gilman's startup earns $190M-plus in Roche deal American City Business Journals
Apr-06-20 06:26PM	Alnylam, Dicerna Join Forces to Take on Arrowhead GuruFocus.com +10.67%
10:30AM	Former gene-silencing rivals bury the hatchet with new partnership American City Business Journals
07:00AM	Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs Business Wire
Apr-01-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -5.66%
Mar-31-20 07:30AM	Dicerna Provides Initial Observations From PHYOX3 Trial of Nedosiran for Treatment of Primary Hyperoxaluria and an Update on Data Presentation Plan Business Wire
Mar-26-20 04:05PM	Dicerna Addresses Business Continuity in Response to COVID-19 Pandemic Business Wire
Mar-23-20 06:23PM	Stocks Flashing Renewed Technical Strength: Dicerna Pharmaceuticals Investor's Business Daily +10.61%
Mar-19-20 07:37AM	The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection Benzinga +17.62%
Mar-18-20 04:05PM	Dicerna Receives Orphan Drug Designation From U.S. Food and Drug Administration for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency Business Wire
Mar-09-20 01:25PM	Edited Transcript of DRNA earnings conference call or presentation 27-Feb-20 9:30pm GMT Thomson Reuters StreetEvents -5.48%
Mar-02-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-29-20 08:53AM	Earnings Beat: Dicerna Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Simply Wall St.
Feb-27-20 06:25PM	Dicerna Pharmaceuticals (DRNA) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:05PM	Dicerna Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Business Wire
Feb-20-20 04:05PM	Dicerna to Report Fourth Quarter and Full Year 2019 Financial Results on Feb. 27, 2020 Business Wire
Feb-18-20 04:05PM	Dicerna to Present at Upcoming Investor Conferences Business Wire
Feb-10-20 07:30AM	Dicerna Appoints Stephen Doberstein, Ph.D., to Board of Directors Business Wire +6.21%
Feb-03-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-29-20 12:45PM	3 Charts Suggest Micro-Cap Stocks Are Headed Higher Investopedia
Jan-17-20 05:40PM	Pharma and Biotech Arent Worried About Democratic Candidates Attacks Against Drugmakers Barrons.com
Jan-02-20 04:30PM	Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
08:10AM	Dow Jones Futures Signal Gains To Start 2020: Tesla Deliveries Loom; Google, Disney Test Key Support Investor's Business Daily
07:30AM	Dicerna Announces Closing of Agreement With Novo Nordisk for Discovery and Development of RNAi Therapies for Liver-Related Cardio-Metabolic Diseases Business Wire
Jan-01-20 07:40AM	We've made it to 2020. These are the top business issues to look for in the new year American City Business Journals
Dec-19-19 07:30AM	Dicerna Announces Closing of Worldwide Collaboration and Licensing Agreement With Roche for Treatments for Chronic Hepatitis B Virus Infection Business Wire
Dec-18-19 11:03AM	Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU Zacks
Dec-17-19 04:12PM	Biotech Succeeds With Gene-Silencing Drug But Its Stock Rally Fails Investor's Business Daily
07:30AM	Dicerna Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency Business Wire
06:00AM	Atlas, MPM, Partners funnel $49M into a new gene-silencing startup American City Business Journals
Dec-16-19 08:00AM	Alexion Exercises Option for Two Additional GalXC RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna Business Wire
Dec-15-19 08:46AM	The Dicerna Pharmaceuticals (NASDAQ:DRNA) Share Price Has Soared 805%, Delighting Many Shareholders Simply Wall St.
Dec-08-19 03:46PM	Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc (DRNA) Insider Monkey
Dec-03-19 08:29AM	Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 10.1% Zacks
Dec-02-19 04:30PM	Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire +10.06%

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Weissman James B	Chief Operating Officer & EVP	Jan 12	Sale	24.08	5,808	139,868	28,060	Jan 13 08:20 PM
Brown Bob D	See Remarks	Jan 12	Sale	24.07	5,808	139,817	26,517	Jan 13 08:20 PM
Weissman James B	Chief Operating Officer & EVP	Jan 11	Sale	23.99	3,800	91,162	33,868	Jan 12 09:40 PM
Koppel Adam	Director	Dec 10	Sale	23.40	1,000,000	23,400,000	3,080,237	Dec 14 05:35 PM
Weissman James B	Chief Operating Officer & EVP	Dec 01	Option Exercise	3.42	4,360	14,911	36,220	Dec 03 08:24 PM
Brown Bob D	See Remarks	Dec 01	Option Exercise	3.42	8,185	27,993	34,702	Dec 03 08:26 PM
Brown Bob D	See Remarks	Dec 01	Sale	25.19	8,185	206,206	26,517	Dec 03 08:26 PM
Weissman James B	Chief Operating Officer & EVP	Dec 01	Sale	25.21	4,360	109,903	31,860	Dec 03 08:24 PM
Paglia Regina M.	Chief Human Resources Officer	Nov 04	Option Exercise	12.93	30,000	387,900	30,000	Nov 06 05:58 PM
Paglia Regina M.	Chief Human Resources Officer	Nov 04	Sale	22.75	30,000	682,500	0	Nov 06 05:58 PM
Weissman James B	Chief Operating Officer & EVP	Nov 02	Option Exercise	3.42	4,360	14,911	36,220	Nov 03 08:19 PM
Brown Bob D	See Remarks	Nov 02	Option Exercise	3.42	8,185	27,993	34,702	Nov 03 08:23 PM
Weissman James B	Chief Operating Officer & EVP	Nov 02	Sale	20.95	4,360	91,333	31,860	Nov 03 08:19 PM
Brown Bob D	See Remarks	Nov 02	Sale	21.03	8,185	172,131	26,517	Nov 03 08:23 PM
Weissman James B	Chief Operating Officer & EVP	Oct 20	Option Exercise	2.97	10,000	29,700	31,860	Oct 22 08:45 PM
Brown Bob D	See Remarks	Oct 16	Option Exercise	3.42	16,370	55,985	42,887	Oct 20 07:32 PM
Brown Bob D	See Remarks	Oct 16	Sale	21.00	16,370	343,770	26,517	Oct 20 07:32 PM
Weissman James B	Chief Operating Officer & EVP	Oct 15	Option Exercise	3.42	8,720	29,822	30,580	Oct 19 09:59 PM
Weissman James B	Chief Operating Officer & EVP	Oct 15	Sale	20.20	8,720	176,144	21,860	Oct 19 09:59 PM
Brown Bob D	See Remarks	Sep 16	Option Exercise	3.42	21,250	72,675	26,517	Sep 18 08:03 PM
Brown Bob D	See Remarks	Sep 14	Option Exercise	3.42	267	913	5,267	Sep 16 08:01 PM
FAMBROUGH DOUGLAS	President and CEO	Sep 01	Buy	18.06	10,000	180,597	22,300	Sep 01 08:33 PM
Brown Bob D	See Remarks	Aug 03	Option Exercise	3.42	8,185	27,993	13,185	Aug 05 07:00 PM
Weissman James B	EVP & Chief Operating Officer	Aug 03	Option Exercise	3.00	4,360	13,066	26,220	Aug 05 07:01 PM
Brown Bob D	See Remarks	Aug 03	Sale	22.48	8,185	183,987	5,000	Aug 05 07:00 PM
Weissman James B	EVP & Chief Operating Officer	Aug 03	Sale	22.47	4,360	97,978	21,860	Aug 05 07:01 PM
Brown Bob D	See Remarks	Jul 01	Option Exercise	3.42	8,185	27,993	13,185	Jul 06 09:01 PM
Weissman James B	Chief Operating Officer & EVP	Jul 01	Option Exercise	2.97	4,360	12,949	26,220	Jul 06 09:00 PM
Brown Bob D	See Remarks	Jul 01	Sale	26.50	8,185	216,929	5,000	Jul 06 09:01 PM
Weissman James B	Chief Operating Officer & EVP	Jul 01	Sale	26.53	4,360	115,679	21,860	Jul 06 09:00 PM
Brown Bob D	See Remarks	Jun 19	Option Exercise	2.97	9,670	28,720	14,670	Jun 23 08:01 PM
Brown Bob D	See Remarks	Jun 19	Sale	25.00	9,670	241,750	5,000	Jun 23 08:01 PM
Brown Bob D	See Remarks	Jun 01	Option Exercise	3.42	8,185	27,993	13,185	Jun 02 08:00 PM
Weissman James B	Chief Operating Officer & EVP	Jun 01	Option Exercise	2.97	4,360	12,949	26,220	Jun 02 08:02 PM
Brown Bob D	See Remarks	Jun 01	Sale	21.01	8,185	171,959	5,000	Jun 02 08:00 PM
Weissman James B	Chief Operating Officer & EVP	Jun 01	Sale	21.06	4,360	91,807	21,860	Jun 02 08:02 PM
Brown Bob D	See Remarks	May 11	Option Exercise	2.97	13,281	39,445	18,281	May 12 08:00 PM
Brown Bob D	See Remarks	May 11	Sale	24.00	13,281	318,744	5,000	May 12 08:00 PM
Brown Bob D	See Remarks	May 05	Option Exercise	3.42	8,185	27,993	13,185	May 07 08:01 PM
Brown Bob D	See Remarks	May 05	Sale	21.00	8,185	171,885	5,000	May 07 08:01 PM
Weissman James B	Chief Operating Officer & EVP	May 04	Option Exercise	2.97	4,360	12,949	26,220	May 06 08:00 PM
Weissman James B	Chief Operating Officer & EVP	May 04	Sale	20.20	4,360	88,072	21,860	May 06 08:00 PM
Brown Bob D	See Remarks	Apr 20	Option Exercise	2.97	13,281	39,445	18,281	Apr 21 08:01 PM
GREEN JOHN B	Chief Financial Officer	Apr 20	Option Exercise	5.45	25,624	139,651	45,045	Apr 22 08:00 PM
GREEN JOHN B	Chief Financial Officer	Apr 20	Sale	22.95	25,624	588,071	19,421	Apr 22 08:00 PM
Brown Bob D	See Remarks	Apr 20	Sale	23.00	13,281	305,463	5,000	Apr 21 08:01 PM
Brown Bob D	See Remarks	Apr 17	Option Exercise	3.42	8,185	27,993	13,185	Apr 21 08:01 PM
Brown Bob D	See Remarks	Apr 17	Sale	21.18	8,185	173,358	5,000	Apr 21 08:01 PM
Weissman James B	Chief Operating Officer & EVP	Apr 13	Option Exercise	2.97	4,360	12,949	26,220	Apr 14 08:33 PM
Weissman James B	Chief Operating Officer & EVP	Apr 13	Sale	20.20	4,360	88,072	21,860	Apr 14 08:33 PM
GREEN JOHN B	Chief Financial Officer	Apr 07	Option Exercise	3.88	20,469	79,395	39,890	Apr 09 08:13 PM
GREEN JOHN B	Chief Financial Officer	Apr 07	Sale	19.95	20,469	408,357	19,421	Apr 09 08:13 PM
Weissman James B	EVP & Chief Operating Officer	Mar 02	Option Exercise	2.97	4,360	12,949	26,220	Mar 03 08:30 PM
Brown Bob D	See Remarks	Mar 02	Option Exercise	3.42	8,185	27,993	13,185	Mar 03 08:31 PM
Brown Bob D	See Remarks	Mar 02	Sale	21.00	8,185	171,885	5,000	Mar 03 08:31 PM
Weissman James B	EVP & Chief Operating Officer	Mar 02	Sale	20.61	4,360	89,854	21,860	Mar 03 08:30 PM
Brown Bob D	See Remarks	Feb 10	Option Exercise	3.42	8,185	27,993	13,185	Feb 11 08:01 PM
Brown Bob D	See Remarks	Feb 10	Sale	21.00	8,185	171,885	5,000	Feb 11 08:01 PM
Weissman James B	EVP & Chief Operating Officer	Feb 03	Option Exercise	2.97	4,360	12,949	26,220	Feb 04 08:03 PM
Weissman James B	EVP & Chief Operating Officer	Feb 03	Sale	20.20	4,360	88,072	21,860	Feb 04 08:03 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience